Objective: This study researched prevalence rates of depression and suicide-related behaviors, targeting military executives, and tried to figure out suicide-related attitude and level of awareness. Moreover, this study suggested factors required for military-specialized psychological autopsy, and sought for construction plan about suicide prevention system for military executives. Methods: This study conducted literature search, onlinesurvey, case analysis of military suicide, and psychological autopsy suggestion. In literature search, references evaluating effect of military suicide prevention strategy were searched in the systemic review. 3,289 references were found, and 9 references were finally selected. Research targets were all of military executives belong to 3 military infantry divisions and 1 air-force fighter wing, and data of 3,339 out of 4,796 were used. The research contents were as follows; depression(CES-D), suicide ideation/plan/attempt, psychological treatment, anxiety(HDAS), problematic alcohol use(ASSIST-Lite), negative daily life incidents.
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Targeting the dopamine 1 receptor or its downstream signalling by inhibiting phosphodiesterase-1 improves cognitive performance Anton Pekcec, Niklas Schülert, Riccardo Giovannini, Roland Pfau, Birgit Stierstorfer, Scott Hobson, Holger Rosenbrock Boehringer Ingelheim Pharma GmbH & Co KG, Div. Research, 88397 Biberach, Germany Abstract Insufficient prefrontal dopamine 1 receptor (D1R) signalling has been linked to cognitive dysfunction in several psychiatric conditions. Since the phosphodiesterase-1 (PDE1) is postulated to regulate D1R-dependent signal transduction, the study intends to elucidate the role of PDE1 for cognitive processes reliant on D1R function.
Pro-cognitive effects of the D1R agonist, SKF38393, were studied in the rat 5-Choice Serial Reaction Time Task (5CSRTT).
Mechanistic studies on modulation of neuronal transmission by SKF38393 were performed using extracellular recordings from rat prefrontal slices. D1R-PDE1 double-immunohistochemistry was performed using human and rat brain sections. Potency of the PDE1-inhibitor (PDE-I: WO2013/192556) was determined in assays using recombinant human PDE1A, 1B and 1C expressed in a baculoviral system. PDE-I was administered to mice and the increase of cAMP/cGMP was determined in prefrontal tissue via ELISA. Effects of PDE1-I on working memory performance were tested in the mouse T-maze continuous alternation task.
SKF38393 improves attention in in the 5CSRTT and increases synaptic transmission in the prefrontal cortex. Double immunohistochemistry revealed PDE1-D1R co-localization cortical structures. PDE-I proves to be a potent PDE1A, 1B, 1C inhibitor (IC 50 = 31-75 pM), and PDE-I administration results in a dosedependent increase of cAMP/cGMP in the prefrontal cortex and reversed MK-801 induced working memory impairments in the mouse T-maze task.
The data support the link between PDE1 and D1R, suggest that PDE1 regulates D1R signalling by modulating cAMP levels, highlights the role of this pathway in cognitive processes, and support the use of PDE1 inhibitors as a potential approach for the treatment of cognitive dysfunction.
